Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous CMV-pp65-flLAMP mRNA-loaded dendritic cell vaccine

A cancer cell vaccine consisting of autologous dendritic cells (DCs) loaded with mRNA encoding the human cytomegalovirus (CMV) matrix protein pp65 (65 kDa lower matrix phosphoprotein; UL83) as a fusion protein with the full-length lysosome-associated membrane protein (flLAMP), with potential immunostimulatory and antineoplastic activities. Upon vaccination, the autologous CMV-pp65-flLAMP mRNA loaded DC vaccine exposes the immune system to the CMV pp65 peptide, which may elicit a cytotoxic T-lymphocyte (CTL) response against CMV pp65-expressing tumor cells. The incorporation of flLAMP may route CMV pp-65 antigens into the lysosomal compartment, resulting in enhanced MHC class II antigen presentation, thereby promoting CD4-positive T-cell responses. The CMV pp65 protein is the primary component of the enveloped subviral particle of CMV and is expressed in certain tumor types.
Synonym:autologous CMV pp65-LAMP mRNA-loaded DC vaccine
autologous CMV-pp65-flLamp DCs
autologous flLAMP-pp65 mRNA-pulsed DC vaccine
autologous flLAMP-pp65-DC vaccine
autologous flLAMP-pp65-DCs
autologous pp65-flLAMP DC vaccine
autologous pp65-flLAMP DCs
Search NCI's Drug Dictionary